French artificial heart maker Carmat filed for insolvency with the Versailles Economic Affairs Court, seeking receivership. The company also requested Euronext to suspend trading of its ALCAE shares as of June 30.
Carmat warned in late June it needed an additional €3.5 million immediately and about €35 million over the next year to continue operations. Despite financial challenges, it continues exploring options to sustain business activities.
This comes weeks after Carmat reported the first commercial implants of its Aeson artificial heart outside the EU, with two procedures performed in Israel.
In 2024, Carmat posted €7 million in revenue but suffered a net loss exceeding €51 million. Founded in 2008, Carmat aims for Aeson to become a leading alternative to heart transplants for end-stage biventricular heart failure.
Follow MEDWIRE.AI for artificial heart and cardiac device industry updates.
